尿微量白蛋白和N-末端脑钠肽前体在心力衰竭中的临床价值被引量：1

在线阅读下载PDF

导出

摘要目的研究慢性心力衰竭(CHF)患者尿微量白蛋白(MAU)与血浆N-末端脑钠肽前体(NT-pro BNP)的相关性。方法选取收治的心衰患者70例为治疗组,选择体检者中完全健康的20例作为对照组,比较2组NT-pro BNP、MAU水平,分析MAU与NT-pro BNP的相关性。结果随着心衰患者心功能的恶化,血浆NTpro BNP及MAU均呈上升趋势(P<0.05);心衰患者MAU和左室射血分数(LVEF)存在负相关(r=-0.668,P<0.05),NT-pro BNP和MAU之间存在正相关(r=0.781,P<0.05)。结论心衰患者检测MAU水平可在一定程度上代替NT-pro BNP的测定。

作者罗萍马涛杨丽萍张艳丽

机构地区宁夏第三人民医院心内科宁夏青铜峡市人民医院宁夏医科大学

出处《宁夏医学杂志》 CAS 2015年第12期1128-1130,共3页 Ningxia Medical Journal

关键词心力衰竭 N-末端脑钠肽前体尿微量白蛋白左室射血分数

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献8

1周秋菊,李志勇.慢性心力衰竭患者尿微量白蛋白与心功能关系的探讨[J].心脑血管病防治,2012,12(2):152-153. 被引量：6
2Mcmurray JJ, Adamopoulos S, Anker SD, et aL ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 : the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology, developed in collaboration with the heart [ J]. European Heart Journal,2012, 33(14) :1787 - 1847.
3无.中国心力衰竭诊断和治疗指南2014[J].中国实用乡村医生杂志,2014,0(24):3-10. 被引量：177
4Porcel JM. Utilization of B-type natriuretic peptide and NT- proBNP in the diagnosis of pleural effusions due to heart failure[J]. Cmrent O-pinion in Pulmonary Medicine, 2011,17 ( 4 ) : 215 - 219.
5Savarese G, Trimarco B, Dellegrottaglie S, et al. Natriuretic peptide - guided therapy in chronic heart failure : a meta - analysis of 2, 686 patients in 12 randomized trims [ J ]. PLOS One, 2013,8 (3) :e58287.
6王学东,佴静,汪钰,王婷姝,郑红晓,刘京峰.慢性心力衰竭患者血清尿酸与尿微量白蛋白的关系[J].山东医药,2011,51(8):86-87. 被引量：2
7张道进,陈晓健,赵健锋.依那普利与氯沙坦联用治疗高血压并发2型糖尿病患者微量白蛋白尿的临床疗效[J].中国实用医药,2011,6(2):3-4. 被引量：6
8袁飞.老年慢性心力衰竭患者微量白蛋白尿水平及其影响因素[J].中国老年学杂志,2015,35(3):581-582. 被引量：6

二级参考文献36

1柏淑禹,郑闻,陈茂华,龚海燕.原发性高血压患者微量白蛋白尿与心脏结构改变的关系[J].实用老年医学,2005,19(1):44-46. 被引量：9
2Mattock MB,Morrish NJ,Viberti G,et al.Prospective study of mi2croalbu minuria as p redictor of mortality in N1DDM.D iabetes,1992,41(6):736-741.
3Segura J,Ruilope LM,Rodicio JL.Microalbuminuria.Clin Exp Hypertens,2004,26(728):701-707.
4Brenner BM,CooperME,de Zeeuw D,et al.Effects of losartan on re2nal and cardiovascular outcomes in patientswitn type 2 diabetes and nephropathy.N Engl J M ed,2001,345(12):861-869.
5Schiffrin EL,Park JB,Intengan HD,et al.Correction of arterial struc2ture and endothelial dysfunction in human essential hypertension by the angiotensin recep tor antagonist losartan.Circulation,2000,101(14):1653-1659.
6Clausen P,Jensen G,Borch-Johnsen K,et al.Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects[J].Circulation,2001,103(14):1869-1874.
7Doehner W,Anker SD.Uric acid in chronic heart failure[J].Semin Nephrol,2005,25(1):61-66.
8Bergamini C,Cicoira M,Rossi A,et al.Oxidative stress and hyperuricaemia:pathophysiology,clinical relevance,and therapeutic implications in chronic heart failure[J].Eur J Heart Fail,2009,11(5):444-452.
9Doehner W,Springer J,Landmesser U,et al.Uric acid in chronic heart failure-current pathophysiological concepts[J].Eur J Heart Fail,2008,10(12):1269-1270.
10George J,Struthers AD.Role of urate,xanthine oxidase and the effects of allopurinol in vascular oxidative stress[J].Vasc Health Risk Manag,2009,5(1):265-272.